Epizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
January 03 2017 - 6:30AM
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical
company creating novel epigenetic therapies, today announced that
Robert Bazemore, chief executive officer of Epizyme, will present a
company overview at the J.P. Morgan 35th Annual Healthcare
Conference on Monday, January 9, 2017 at 12:00 p.m. PT. The
conference is taking place January 9-12, 2017 at the Westin St.
Francis in San Francisco.
To access the live webcast of Epizyme’s
presentation, please visit the Events & Presentations page
within the Investor page of the website at www.epizyme.com. Replays
of the webcast will be available on the Epizyme website for 90 days
following the conference.
About Epizyme, Inc. Epizyme,
Inc. is a clinical stage biopharmaceutical company creating novel
epigenetic therapeutics for cancer patients. Epizyme has built a
proprietary product platform that the Company uses to create small
molecule inhibitors of a 96-member class of enzymes known as
histone methyltransferases, or HMTs. HMTs are part of the system of
gene regulation, referred to as epigenetics, that controls gene
expression. Genetic alterations can result in changes to the
activity of HMTs, making them oncogenic (cancer-causing). By
focusing on the genetic drivers of cancers, Epizyme's targeted
science seeks to match the right medicines with the right patients.
For more information, visit www.epizyme.com.
Media Contact:
Julie DiCarlo, Epizyme, Inc.
(617) 306-5823
jdicarlo@epizyme.com
Investor Contact:
Monique Allaire, THRUST Investor Relations
(617) 895-9511
monique@thrustir.com
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2023 to Apr 2024